Results 41 to 50 of about 6,725 (159)

Comparison Study of the Safety Profile of Olaparib Versus Niraparib: Analysis of Real-World Data from EudraVigilance

Pharmaceuticals
Background: Olaparib and niraparib are poly (ADP-ribose) polymerase inhibitors (PARPi) used primarily for the treatment of ovarian cancer. While both drugs have demonstrated efficacy in clinical trials, their safety profiles, particularly in real-world ...
Desirèe Speranza, Fausto Omero, Vincenzo Cianci, Mariapia Marafioti, Carla Infurna, Patrizia Carroccio, Edoardo Spina, Maria Antonietta Barbieri, Emanuela Esposito, Nicola Silvestris, Mariacarmela Santarpia   +10 more
doaj   +1 more source

Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) caused by niraparib: a novel antineoplastic agent

Allergy, Asthma & Clinical Immunology
Background Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) is a rare but potentially life-threatening hypersensitivity reaction characterized by skin rash, fever, lymphadenopathy, hematologic abnormalities, and organ involvement. Niraparib,
Irene Vázquez-Barrera, Alba Juárez-Guerrero, Cristina Cuevas-Bravo, Patricia Rojas Perez-Ezquerra, Blanca Noguerado-Mellado   +4 more
doaj   +1 more source

Niraparib plays synergistic antitumor effects with NRT in a mouse ovarian cancer model with HRP

Translational Oncology
Objective: PARPi offers less clinical benefit for HRP patients compared to HRD patients. PARPi has an immunomodulatory function. NRT therapy targets tumor neoantigens without off-target immune toxicity.
Jiefang Lu, Haiying Liu, Binming Wang, Chengcheng Chen, Fumao Bai, Xiaoping Su, Ping Duan   +6 more
doaj   +1 more source

Targeting GALNT7 Disrupts the TAZ O‐GalNAcylation Feedback Loop to Suppress Gallbladder Cancer Progression

Advanced Science, Volume 13, Issue 55, 5 October 2026.
Aberrant GALNT7‐mediated O‐GalNAcylation stabilizes TAZ to drive gallbladder cancer progression through a feed‐forward transcriptional loop. Structure‐based screening identifies Olaparib as a potent GALNT7 antagonist that disrupts this oncogenic axis, providing an immediate therapeutic strategy for this aggressive malignancy.
Peng Qiu, Ming Zhang, Yunxiang Feng, Yibo Deng, Kai Zhao, Xiangyu Li, Yun Lu, Li Tian, Tao Yang, Wei Yao, Jianming Wang, Zhengdong Deng   +11 more
wiley   +1 more source

Targeting Integrins in Triple Negative Breast Cancer: Therapeutic Potential of Monoclonal Antibodies, PARP Inhibitors, Synthetic Peptides, and Aptamers

Cancer Medicine, Volume 15, Issue 10, October 2026.
ABSTRACT Triple‐negative breast cancers (TNBCs) are associated with poor prognosis and chemoresistance. Recent reports indicate that extracellular matrix (ECM) molecules, such as integrins, could influence TNBC development. Integrins are adhesion macromolecules that modulate ECM characteristics such as stiffening of ECM and being associated with ...
Mobina Darabi, Zeynab Zahedi, Kosar Zolfaghari, Alireza Kordi, Kiarash Saleki, Niloufar Yazdanpanah, Nima Rezaei   +6 more
wiley   +1 more source

Combined use of niraparib enhanced the inhibitory effect of Anti-GD2 antibody on osteosarcoma cells

Discover Oncology
Purpose This study aims to investigate the effect of Niraparib in combination with an Anti-GD2 Antibody on osteosarcoma cells. Methods Scratch test was utilized to assess cell migration capacity, while the Transwell experiment was utilized to evaluate ...
Chen Wenyao, Ma Shuai, Fan Yifeng, Li Xinzhi, Que Xiangyong   +4 more
doaj   +1 more source

Niraparib in ovarian cancer: results to date and clinical potential

Therapeutic Advances in Medical Oncology, 2017
Ovarian cancer is the first cause of death from gynaecological malignancy. Germline mutation in BRCA1 and 2 , two genes involved in the mechanisms of reparation of DNA damage, are showed to be related with the incidence of breast and ovarian cancer, both
Davide Caruso, Anselmo Papa, Silverio Tomao, Patrizia Vici, Pierluigi Benedetti Panici, Federica Tomao   +5 more
doaj   +1 more source

Exploring Vitamin D Metabolism in Gynaecological Malignancies: Redox‐Dependent and Redox‐Independent Anticancer Mechanisms From Preclinical Models to Clinical Evidence

Cancer Medicine, Volume 15, Issue 10, October 2026.
ABSTRACT Gynaecological malignancies account for over 1.4 million new diagnoses, with outcomes constrained by late‐stage presentation and chemoresistance. Dysregulated redox homeostasis is a hallmark of tumourigenesis. Tumour cells maintain elevated basal reactive oxygen species (ROS), which support proliferative signalling but may also increase ...
Hoi Ching Cherry Chan, Sachin Bhoora, Esther Zhou, Sumari Marais, Rivak Punchoo   +4 more
wiley   +1 more source

Olaparib‐associated cutaneous vasculitis in a patient with breast cancer

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Marcial Álvarez‐Salafranca, Teresa Puértolas, Adrián Diago, María Carmen Gómez‐Mateo   +3 more
wiley   +1 more source

Next‐Generation Sequencing‐Based Molecular Profiling and Management of Advanced Solid Tumors: A Real‐World Experience in a Community‐Based Academic Cancer Center

Cancer Medicine, Volume 15, Issue 10, October 2026.
ABSTRACT Background Advances in molecular and cell biology have led to a paradigm shift in cancer management. We implemented next‐generation sequencing (NGS) at our community‐based academic cancer center over a decade ago. We sought to optimize the use of genomics and understand its impact in identifying actionable genomic alterations to determine ...
Gayathri Moorthy, Annette Sereika, Karen Kaul, Megan Parilla, Mir B. Alikhan, Michael Bouma, Dyson Wake, Peter J. Hulick, Henry M. Dunnenberger, Linda M. Sabatini, Mathew Yang, Kathy A. Mangold, Erin Proctor, Nicholas Evans, Nicholas Miller, Donald L. Helseth Jr, Darryck Maurer, Justin Brueck, Janardan Khandekar, Bruce Brockstein   +19 more
wiley   +1 more source